Erlotinib
- Generic Name
- Erlotinib
- Brand Names
- Tarceva
- Drug Type
- Small Molecule
- Chemical Formula
- C22H23N3O4
- CAS Number
- 183321-74-6
- Unique Ingredient Identifier
- J4T82NDH7E
- Background
Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is typically marketed under the trade name Tarceva. Erlotinib binds to the epidermal growth factor receptor (EGFR) tyrosine kinase in a reversible fashion...
- Indication
Erlotinib is indicated for:
The safety and efficacy of erlotinib have not been established for patients with NSCLC whose tumors show other EGFR mutations. Additionally it is not recommended for use in combination with platinum-based chemotherapy.
- Associated Conditions
- Locally Advanced Pancreatic Cancer (LAPC), Metastatic Non-Small Cell Lung Cancer, Pancreatic Metastatic Cancer, Unresectable Pancreatic Cancer
- Associated Therapies
- -
Afatinib vs Erlotinib as 2nd TKI After Failure to 1st TKI and Chemotherapy for Metastatic NSCLC
- First Posted Date
- 2015-12-09
- Last Posted Date
- 2015-12-09
- Lead Sponsor
- The University of Hong Kong
- Target Recruit Count
- 25
- Registration Number
- NCT02625168
- Locations
- 🇭🇰
Department of Clinical Oncology, Queen Mary Hospital, Hong Kong, Hong Kong
A Non-interventional Trial of Erlotinib (Tarceva) Metastatic Non-small Cell Lung Cancer
- First Posted Date
- 2015-11-03
- Last Posted Date
- 2016-01-25
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 299
- Registration Number
- NCT02595450
A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations
- Conditions
- Interventions
- First Posted Date
- 2015-10-27
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 530
- Registration Number
- NCT02588261
- Locations
- 🇺🇸
Site US10025, Fountain Valley, California, United States
🇺🇸Site US10003, Santa Monica, California, United States
🇺🇸Site US10013, Aventura, Florida, United States
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
- First Posted Date
- 2015-10-12
- Last Posted Date
- 2021-05-06
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 341
- Registration Number
- NCT02574078
- Locations
- 🇺🇸
Cancer Care Center, Bismarck, North Dakota, United States
🇺🇸Lehigh Valley Hospital, Allentown, Pennsylvania, United States
🇺🇸Texas Oncology Cancer Center - Sugar Land, Sugar Land, Texas, United States
IMRT Combined With Erlotinib for EGFR Wild Type Non-small Cell Lung Cancer With 4-10 Brain Metastases
- Conditions
- Interventions
- First Posted Date
- 2015-09-22
- Last Posted Date
- 2019-04-12
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 12
- Registration Number
- NCT02556593
- Locations
- 🇨🇳
Hui Liu, Guangdong, China
A Study of Pertuzumab With Erlotinib in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
- First Posted Date
- 2015-07-23
- Last Posted Date
- 2015-10-16
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 17
- Registration Number
- NCT02507375
A Study of ASP2215 in Combination With Erlotinib in Subjects With Epidermal Growth Factor Receptor (EGFR) Activating Mutation-Positive (EGFRm+) Advanced Non-Small-Cell Lung Cancer (NSCLC) Who Have Acquired Resistance to an EGFR Tyrosine Kinase Inhibitor (TKI)
- First Posted Date
- 2015-07-13
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT02495233
- Locations
- 🇯🇵
Site JP81005, Osakasayama, Osaka, Japan
🇯🇵Site JP81004, Fukuoka Minami-ku, Fukuoka, Japan
🇯🇵Site JP81003, Suntogun Nagaizumicho,Shizuoka, Japan
An Extension Study of Onartuzumab in Participants With Solid Tumors on Study Treatment Previously Enrolled in a Company Sponsored Study
- First Posted Date
- 2015-07-02
- Last Posted Date
- 2019-07-23
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 12
- Registration Number
- NCT02488330
- Locations
- 🇫🇷
Hopital Roger Salengro, Lille, France
🇯🇵National Hospital Organization Shikoku Cancer Center, Ehime, Japan
🇮🇹Azienda Ospedaliero Universitaria San Giovanni Battista Di Torino, Torino, Piemonte, Italy
A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET Amplification
- Conditions
- Interventions
- First Posted Date
- 2015-06-11
- Last Posted Date
- 2020-02-24
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 23
- Registration Number
- NCT02468661
- Locations
- 🇺🇸
Henry Ford Hospital SC, Detroit, Michigan, United States
🇺🇸Los Angeles Hematology/Oncology Medical Group, Los Angeles, California, United States
🇺🇸University of California Irvine Medical Center Chao Family SC, Orange, California, United States
Local Therapies for Oligometastatic Non-Small Cell Lung Cancer Harboring Sensitizing EGFR Mutations
- Conditions
- Interventions
- First Posted Date
- 2015-05-21
- Last Posted Date
- 2018-05-21
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 4
- Registration Number
- NCT02450591
- Locations
- 🇺🇸
Memorial Sloan Kettering Westchester, Harrison, New York, United States
🇺🇸Memorial Sloan Kettering at Mercy Medical Center, Rockville Centre, New York, United States
🇺🇸Memoral Sloan Kettering Cancer Center, Basking Ridge, New Jersey, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.